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aBStraCt 
Parvovirus B19 (B19V) can be transmitted by the respiratory route, vertically – from the mother to the fetus – and via blood transfusion 
or organ transplantation. Infection by transfusion of blood or blood products occurs due to the resistance of B19V to viral inactivation 
methods. Our study evaluated the presence of B19V deoxyribonucleic acid (DNA) and the prevalence of anti-B19V class G immunoglobulin 
(IgG) in women of childbearing age blood donors of the Federal District, Brazil. Our results demonstrated the absence of B19V DNA in 
these blood donors. However, the seroprevalence for anti-B19V IgG was observed in 60.7% of this population. This study provides important 
data of B19V circulation in the Center-West of Brazil.
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BriEfing CoMMuniCation
Parvovirus B19 (B19V) belongs to the family Parvoviridae 
(genus Erythrovirus). It is a small (19-25 nm), non-enveloped, 
icosahedral and single-stranded deoxyribonucleic acid (DNA) 
genome virus(1). The viral capsid consists of two structural proteins: 
VP1 and VP2. The viral genome also encodes a NS1 non-structural 
protein, which participates in viral replication and apoptosis of the 
host cell(2).
In most cases, B19V causes a benign infection in children 
known as infectious erythema or fifth disease. However, the virus 
can cause a number of symptoms, including lethal outcome. 
The symptoms related to B19V infection depend on the age, 
immunological condition and mainly the hematological 
condition of the infected individual(3). When infection is acquired 
in adulthood, the clinical presentation is compatible with arthritis 
or arthralgia, especially in the large joints, and may persist 
for years. In individuals with a high erythrocyte turnover rate – for 
example, in individuals with hemoglobinopathies – acute B19V 
infection may lead to transient aplastic crisis(4). In pregnancy, 
o B19V represents a great danger to the fetus by crossing the 
placental barrier and infecting erythroid progenitor cells in 
the bone marrow and liver of the fetus, which can lead to blockage 
of erythropoiesis, severe anemia, fetal hydrops, and death(5).
B19V has multiple transmission mechanisms, including 
respiratory route transmission, vertical transmission from mother 
to fetus, and by bone marrow and solid organ transplantation(6). 
Due to the high rates of persistence of the virus in the blood, the 
resistance to pathogen inactivation processes and the fact that 
it can cause an asymptomatic infection, there is a possibility 
of transmission also through transfusion of blood and blood 
components, mainly with the therapeutic use of coagulation 
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factors derived from human plasma(7). Considering the possibility 
of B19V transmission by blood transfusion, this study aimed to 
evaluate the presence of B19V DNA circulating plasma obtained 
from a group of blood donors from the Blood Center of Brasília, 
Federal District, Brazil, more specifically in women of childbearing 
age. There is still little information on the circulation of B19V 
in the Center-West of Brazil, and no information in the Federal 
District. The project was approved by the Human Research Ethics 
Committee (CAAE: 62718016.0.0000.5553). 
A total of 89 serum samples were randomly collected from 
women aged between 20-38 years (mean of 28.5 years), previously 
stored in serum bank at -80°C in December 2015. Viral DNA was 
extracted from 200 µl of serum, using PureLink™ Viral RNA/DNA 
Mini Kit (Invitrogen – ThermoFisher Scientific, São Paulo, Brazil), 
following the manufacturer’s recommendations. After extraction 
of the viral DNA, the molecular detection of B19V was performed 
by the real-time polymerase chain reaction (PCR) methodology 
(TaqMan® technology) as described in the literature(8). In addition 
to the 1X TaqMan Real-time PCR MasterMix reagent (ThermoFisher 
Scientific, São Paulo, Brazil), the following primers were used at the 
concentration of 300 nM: VP1F (5’-GGCCCATTTTCAAGGAAGTT-3) 
and VP1R (5’-GAAGCCAGCACTGGTGCA-3’). The VP1P probe 
(5’-FAM-TACAACGCCTCAGAAAA-3’-MGB) at the concentration 
of 150 nM was also used. The primers and probes were designed 
for a highly conserved portion of the VP1 gene, ensuring the 
detection of all genotypes. The final volume of the reaction was 
25 μl. All reactions were performed in ABI 7500 thermal cycler, 
following standard amplification protocol (50°C for 5 min, 95°C 
denaturation for 5 min and 40 cycles at 95°C for 15s and 60°C 
for 1 min). The sensitivity of this reaction was 10 copies/reaction, 
evaluated by the use of a plasmid(8) containing the sequence 
of interest (VP1 gene fragment of the B19V) in serial dilution of 
108-1 copy/reaction magnitude.
Our study did not demonstrate molecular positivity for the 
B19V DNA in the studied group (Table). However, the prevalence 
of B19V DNA may vary significantly depending on the region and 
evaluated target group. In this regard, in Brazil, other studies have 
demonstrated the presence of B19V DNA in 0% to 1% of blood 
donors in the Southeast region(8-10), and one of these studies with 
a number of donors similar to ours (91 individuals). However, the 
study conducted in the Southeast region includes both male and 
female donors, whereas our study has a relatively homogeneous 
group, i.e. women of childbearing age. In addition, the difference in 
geographical location between studies is also an important factor 
and should be considered. All previous studies were carried out in 
the state of São Paulo, a more populous region when compared to 
the Federal District. In addition, although the different genotypes 
(1, 2 and 3) circulate together, there is a difference in their relative 
frequencies(11). Therefore, there may be differences between 
the B19V genotypes circulating in each region, influencing the 
difference in prevalence between the studies.
In the world context, the B19V DNA prevalence in blood donors 
ranges between 0.006% and 0.88%(2). Another possibility regarding 
the lack of detection of B19V DNA may be related to the absence 
of viral persistence in blood donors evaluated. On the other hand, 
even if viral DNA were detected, it would not be possible to state that 
there would be necessarily a risk of transfusion transmission. The 
persistence of B19V has been demonstrated in different tissues, such 
as skin, liver, heart, among others. After acute infection, genomes 
or fragments of viral DNA can also be released into plasma from 
these tissues and thus the presence of B19V DNA in plasma would 
not necessarily be associated with the presence of the infectious 
viral particle(12). It is still possible that in previous studies the 
rates of persistent infection in blood donors (very low detectable 
DNA load) are higher when compared to our donor group. In this 
regard, the absence of viral DNA in blood donors evaluated in our 
study does not allow us to affirm that the risk of transmission of 
B19V, through blood transfusion at the evaluated blood bank, does 
not exist. Thus, for the evaluation of the true prevalence of B19V 
DNA in this blood bank, it is necessary to include a much higher 
number of samples similarly to all the studies carried out in Brazil 
and by international groups.
Subsequently, the seroprevalence of anti-B19V class G 
immunoglobulin (IgG) was evaluated in the same samples. 
The importance of this evaluation in women of childbearing 
age is justified by the fact that once non-immunized (anti-B19V 
taBLE − Comparison of prevalence of anti-B19V IgG and B19V DNA in studies conducted in Brazil
Study Region (State) Population n anti-B19V IgG B19V (DNA)
Slavov et al. (2012)(8) São Paulo Blood donors (both sexes) 100 60% 1%
Slavov et al. (2012)(9) São Paulo Blood donors (both sexes) 47 57.4% 0%
Slavov et al. (2014)(13) São Paulo Blood donors (both sexes) 40 50% 0%
Slavov et al. (2016)(10) São Paulo Blood donors (both sexes) 91 - 1%
Rios et al. (2016)(14) Goiás Women of childbearing age 101 8.9% -
Silva et al. (2018)(our study) Federal District Blood donors, women of childbearing age 89 60.7% 0%
IgG: class G immunoglobulin; DNA: deoxyribonucleic acid.
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IgG negative), these women are susceptible to infection. In case 
the infection occurs during pregnancy, especially in the first 
trimester, fetal anemia, hydrops, fetal death and spontaneous 
abortion may occur(15). Part of the serum collected was tested 
by the Elisa technique using the Biotrin Parvovirus B19 IgG kit 
(DiaSorin, Saluggia, VC, Italy) according to the manufacturer’s 
recommendations. Our results demonstrated 60.7% seroprevalence 
of anti-B19V IgG in the studied group. The seroprevalence of anti-
B19V IgG in healthy blood donors in different parts of the world 
may range from 9.78% and 79.1%, depending on the geographical 
region and the test used for diagnosis(2). In Brazil, serum levels 
in donors vary between 50% and 60%(8, 9, 13), similar to our results 
the results obtained by our study (Table). This demonstrates that 
although detection of viral DNA in different parts of Brazil varies, 
anti-B19V IgG seroprevalence are relatively close and considered 
high. On the other hand, another study carried out with 101 
women of childbearing age (25 to 34 years old) observed anti-
B19V IgG positivity in 8.9% of the tested individuals in the city of 
Goiânia, Goiás, Central-West Brazil(14). Despite the similar number 
of individuals tested in the Goiânia study and in this study, there 
was a considerable difference in the anti-B19V IgG seroprevalence. 
This difference may occur due to different causes, such as different 
kits used for the detection of IgG [ELISA Ridascreen Parvovirus B19 
rESuMo 
O parvovírus B19 (B19V) pode ser transmitido por via respiratória, verticalmente – da mãe para o feto – e via transfusão de 
sangue e transplante de órgãos. A infecção por transfusão de sangue ou hemoderivados ocorre devido à resistência do B19V 
aos métodos de inativação viral. Nosso estudo avaliou a presença do ácido desoxirribonucleico (DNA) B19V e a prevalência de 
imunoglobulina da classe G (IgG) anti-B19V em mulheres em idade fértil, doadoras de sangue do Distrito Federal, Brasil. Nossos 
resultados demonstraram a ausência de DNA de B19V nesses doadores. No entanto, foi observada a soroprevalência de IgG 
anti-B19V em 60,7% dessa população. Este estudo fornece dados importantes da circulação do B19V no Centro-Oeste do Brasil. 
Unitermos: eritrovírus; parvovírus B19 humano; prevalência; estudos soroepidemiológicos.
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